-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In order to encourage the development of the pharmaceutical industry and reduce the cost of drugs for patients, the Ministry of Finance, the General Administration of Customs, the State Administration of Taxation and the State Drug Administration announced the third batch of anti-cancer drugs and rare disease drugs subject to the value-added tax policy on
the 21st.
the 21st.
From December 1, 2022, the anti-cancer drugs and rare disease drugs included in the list will be subject to the relevant VAT policy in accordance with the previously announced policy
.
The third batch of lists involves more than 70 kinds of
preparations, APIs, etc.
.
The third batch of lists involves more than 70 kinds of
preparations, APIs, etc.
The Ministry of Finance, the General Administration of Customs, the State Administration of Taxation, and the State Medical Products Administration announced in April 2018 that from May 1, 2018, general VAT taxpayers who produce, sell, wholesale, and retail anti-cancer drugs can choose to pay VAT at a rate of 3% according to the simplified method; For imported anti-cancer drugs, import value-added tax
will be levied at a reduced rate of 3%.
will be levied at a reduced rate of 3%.
In February 2019, the Ministry of Finance, the General Administration of Customs, the State Administration of Taxation and the State Medical Products Administration announced that from March 1, 2019, general VAT taxpayers who produce, sell, wholesale, and retail rare disease drugs can choose to pay VAT at a rate of 3% according to the simplified method.
For imported rare disease drugs, import value-added tax
will be levied at a reduced rate of 3%.
For imported rare disease drugs, import value-added tax
will be levied at a reduced rate of 3%.
The Ministry of Finance and other four departments emphasized that the anti-cancer drugs and rare disease drug preparations in each batch of lists need to have been approved for marketing, and the corresponding dosage forms are subject to the actual dosage forms approved by the national drug regulatory authorities
.
.
